AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10562782 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 75
Study 2084587 — intervention group
Group type: EXPERIMENTAL
Intervention: Train of four (TOF) at 10 sec intervals
Number of subjects: 39
Study 2084587 — intervention group
Group type: COMPARATOR
Intervention: Train of four (TOF) at 20 sec intervals
Number of subjects: 39
Study 2084587 — intervention group
Group type: EXPERIMENTAL
Intervention: Single twitch stimulation (STS) at 10 sec intervals
Number of subjects: 39
Study 2084587 — intervention group
Group type: COMPARATOR
Intervention: Single twitch stimulation (STS) at 20 sec intervals
Number of subjects: 39
Study 353274 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Number of subjects: 33
Study 353274 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 33
Study 353274 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 30039453 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) based care and tailored interventions by a multidisciplinary team in an Ambulatory Geriatric Unit, in addition to usual care.
Number of subjects: 382
Study 30039453 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 382
Study 30039453 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA) based care.
Number of subjects: 382
Study 28494455 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing for specific IgE antibodies against Bet v 6
Number of subjects: 57
Study 28494455 — intervention group
Group type: COMPARATOR
Intervention: Control group tested for specific anti-Bet v 6
Number of subjects: 57
Study 26488737 — intervention group
Group type: EXPERIMENTAL
Intervention: Aloe vera-olive oil (AVO) cream
Number of subjects: 60
Study 26488737 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin cream
Number of subjects: 60
Study 23877309 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP (10 cmH2O)
Number of subjects: 32
Study 23877309 — intervention group
Group type: COMPARATOR
Intervention: ZEEP (0 cmH2O)
Number of subjects: 32
Study 22728692 — intervention group
Group type: EXPERIMENTAL
Intervention: lamivudine plus ADV
Number of subjects: 72
Study 22728692 — intervention group
Group type: EXPERIMENTAL
Intervention: telbivudine plus ADV
Number of subjects: 72
Study 22728692 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 72
Study 19776407 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated influenza vaccine
Number of subjects: 1952
Study 19776407 — intervention group
Group type: COMPARATOR
Intervention: Live attenuated influenza vaccine
Number of subjects: 1952
Study 17263742 — intervention group
Group type: COMPARATOR
Intervention: i.v. saline (Group I)
Number of subjects: 90
Study 17263742 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. ketamine (0.5 mg/kg) (Group II)
Number of subjects: 90
Study 17263742 — intervention group
Group type: EXPERIMENTAL
Intervention: peritonsillar infiltration of ketamine (0.5 mg/kg) (Group III)
Number of subjects: 90
Study 15215694 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (addition of optional support groups)
Number of subjects: 775
Study 15215694 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intervention
Number of subjects: 775
Study 15215694 — intervention group
Group type: COMPARATOR
Intervention: Control (interactive STD counseling)
Number of subjects: 775
Study 15215694 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (general)
Number of subjects: 775
Study 12189745 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg once daily for 52 weeks)
Number of subjects: 329
Study 12189745 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin + Serenoa repens (160 mg twice daily for 52 weeks)
Number of subjects: 329
Study 9509204 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane (DES)
Number of subjects: 30
Study 9509204 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (ISO)
Number of subjects: 30
Study 7856157 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard CME (3-hour seminar)
Number of subjects: 13099
Study 7856157 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive CME (3-hour seminar + follow-up seminars and free office materials)
Number of subjects: 13099
Study 7856157 — intervention group
Group type: COMPARATOR
Intervention: Control group (no CME)
Number of subjects: 13099
Study 2786422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (0.05, 1 or 2 mg kg‐1 h‐1)
Number of subjects: 0
Study 2786422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (low and high doses)
Number of subjects: 0
Study 2786422 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin (medium dose)
Number of subjects: 0
Study 2786422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7372355 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg pivampicillin twice daily
Number of subjects: 107
Study 7372355 — intervention group
Group type: COMPARATOR
Intervention: 350 mg pivampicillin three times daily
Number of subjects: 107
Study 7372355 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 107
Study 31482853 — intervention group
Group type: EXPERIMENTAL
Intervention: Information and communication technologies (ICTs) including mobile phones, internet, and social media (Facebook, WhatsApp, Skype, Viber) used for communication with separated family members.
Number of subjects: 290
Study 28741796 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped learning model 1
Number of subjects: 0
Study 28741796 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped learning model 2
Number of subjects: 0
Study 28741796 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped learning (both models)
Number of subjects: 0
Study 25626984 — intervention group
Group type: EXPERIMENTAL
Intervention: Conformational positioner (CP)
Number of subjects: 25
Study 25626984 — intervention group
Group type: COMPARATOR
Intervention: Standard positioning, standard crib mattress (SP)
Number of subjects: 25
Study 23611092 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate in two stages: first stage until pH≥7.15, second stage until pH≥7.25 after 6 hours.
Number of subjects: 65
Study 23611092 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate until pH≥7.15 (control group).
Number of subjects: 65
Study 23611092 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate in stages.
Number of subjects: 65
Study 23390829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive counseling based on menu analysis by a dietitian
Number of subjects: 28
Study 23390829 — intervention group
Group type: COMPARATOR
Intervention: Ordinary nutritional counseling (Control group)
Number of subjects: 28
Study 23390829 — intervention group
Group type: COMPARATOR
Intervention: N/A (Healthy population subjects)
Number of subjects: 28
Study 20515211 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 168
Study 20515211 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control group
Number of subjects: 168
Study 17618948 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acids (Travasol 10% at 0.02 mL.kg(‐1).min(‐1))
Number of subjects: 14
Study 17618948 — intervention group
Group type: COMPARATOR
Intervention: Amino acids (Travasol 10% at 0.02 mL.kg(‐1).min(‐1)) with glucose (4 mg.kg(‐1).min(‐1))
Number of subjects: 14
Study 16198818 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with congenital unilateral brain damage (LH damage)
Number of subjects: 46
Study 16198818 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with congenital unilateral brain damage (RH damage)
Number of subjects: 46
Study 16198818 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with congenital unilateral brain damage (large RH lesions)
Number of subjects: 46
Study 16198818 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with congenital unilateral brain damage (small RH lesions)
Number of subjects: 46
Study 16198818 — intervention group
Group type: COMPARATOR
Intervention: Typically developing matched controls
Number of subjects: 46
Study 12468608 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (210 micro mol every 3 months for 9 months)
Number of subjects: 245
Study 12468608 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 10202827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg and saquinavir 400 mg twice daily
Number of subjects: 141
Study 10202827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 600 mg and saquinavir 400 mg twice daily
Number of subjects: 141
Study 10202827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 400 mg and saquinavir 400 mg three times daily
Number of subjects: 141
Study 10202827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir 600 mg and saquinavir 600 mg twice daily
Number of subjects: 141
Study 10202827 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 141
Study 10202827 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir‐saquinavir 600‐600 mg twice daily
Number of subjects: 141
Study 8848902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen 100 mg i.v. 2 min prior to induction of anaesthesia and an additional 100 mg infused in 60 min
Number of subjects: 100
Study 8848902 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 100
Study 8848902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketoprofen
Number of subjects: 100
Study 2286466 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (3 g) single dose
Number of subjects: 32
Study 2286466 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin (400 mg twice daily for three days)
Number of subjects: 32
Study 6779682 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h continuous oxygen therapy
Number of subjects: 30
Study 6779682 — intervention group
Group type: EXPERIMENTAL
Intervention: 12‐h nocturnal oxygen therapy
Number of subjects: 30
Study 6779682 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 30856122 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal tele-homecare
Number of subjects: 96
Study 30856122 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based care (control)
Number of subjects: 96
Study 27438378 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 19
Study 27438378 — intervention group
Group type: COMPARATOR
Intervention: Long Slow Distance Training (LSD)
Number of subjects: 19
Study 25841245 — intervention group
Group type: EXPERIMENTAL
Intervention: Question identification and answering system using evidence summaries with recommendations based on GRADE approach
Number of subjects: 14
Study 25841245 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 14
Study 25841245 — intervention group
Group type: EXPERIMENTAL
Intervention: Question identification and answering system
Number of subjects: 14
Study 23652888 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily shaving with advanced products
Number of subjects: 90
Study 23652888 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily shaving with standard products
Number of subjects: 90
Study 23652888 — intervention group
Group type: COMPARATOR
Intervention: Shaving 2 to 3 times per week with standard products (control group)
Number of subjects: 90
Study 21388554 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (3 times per week for 24 sessions over 8 weeks)
Number of subjects: 0
Study 21388554 — intervention group
Group type: COMPARATOR
Intervention: Waitlist group (no acupuncture treatment for 8 weeks)
Number of subjects: 0
Study 19395971 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening
Number of subjects: 0
Study 19395971 — intervention group
Group type: COMPARATOR
Intervention: Ongoing randomized controlled trials
Number of subjects: 0
Study 17093962 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive focused program
Number of subjects: 242
Study 17093962 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention of physical exercise and relaxation
Number of subjects: 242
Study 17093962 — intervention group
Group type: COMPARATOR
Intervention: Physical intervention
Number of subjects: 242
Study 15519660 — intervention group
Group type: EXPERIMENTAL
Intervention: Alamifovir at a total daily dose ranging from 2.5 to 20mg
Number of subjects: 66
Study 15519660 — intervention group
Group type: EXPERIMENTAL
Intervention: Alamifovir (5mg BID)
Number of subjects: 66
Study 15519660 — intervention group
Group type: EXPERIMENTAL
Intervention: Alamifovir (10mg BID)
Number of subjects: 66
Study 15519660 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 11543734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 300 mg
Number of subjects: 155
Study 11543734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol augmentation
Number of subjects: 155
Study 11543734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study 9209187 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Fe, 750 micrograms retinol, 250 micrograms folic acid, and 60 mg vitamin C per day
Number of subjects: 273
Study 9209187 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg Fe, 6000 micrograms retinol, 500 mg folic acid, and 60 mg vitamin C once a week
Number of subjects: 273
Study 9209187 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 mg Fe and the same amount of the other three micronutrients as the second group once a week
Number of subjects: 273
Study 9209187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 273
Study 7699373 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged epidural anesthesia (48 hours)
Number of subjects: 120
Study 7699373 — intervention group
Group type: COMPARATOR
Intervention: General endotracheal anesthesia
Number of subjects: 120
Study 3582475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine alone (150 mg)
Number of subjects: 10
Study 3582475 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine with aluminum phosphate (11 g)
Number of subjects: 10
Study 31327701 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery denervation (RAD)
Number of subjects: 0
Study 31327701 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 29855352 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by SA community health workers at 6, 8, 10, 12, 14, and 16 months of age
Number of subjects: 360
Study 29855352 — intervention group
Group type: COMPARATOR
Intervention: Culturally tailored educational material
Number of subjects: 360
Study 29855352 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visits by SA community health workers
Number of subjects: 360
Study 26361281 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-delayed MRI with gadobenate dimeglumine (0.1-mmol/kg) administered immediately, followed by 2 axial T1-weighted sequences after 5-minute intervals (final image acquisition at 15 minutes).
Number of subjects: 38
Study 25917319 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher levels of HRV among participants instructed to suppress thoughts
Number of subjects: 0
Study 25917319 — intervention group
Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 0
Study 25917319 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting HRV
Number of subjects: 0
Study 25917319 — intervention group
Group type: EXPERIMENTAL
Intervention: HRV-related differences in thought suppression success
Number of subjects: 0
Study 23103452 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 629
Study 23103452 — intervention group
Group type: COMPARATOR
Intervention: Booster training
Number of subjects: 629
Study 23103452 — intervention group
Group type: COMPARATOR
Intervention: Training adherence
Number of subjects: 629
Study 23103452 — intervention group
Group type: COMPARATOR
Intervention: Baseline age
Number of subjects: 629
Study 23103452 — intervention group
Group type: COMPARATOR
Intervention: Higher education
Number of subjects: 629
Study 23103452 — intervention group
Group type: COMPARATOR
Intervention: Better self-rated health
Number of subjects: 629
Study 18653261 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) adherence in smoking cessation sessions
Number of subjects: 84
Study 18653261 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) adherence
Number of subjects: 84
Study 18779890 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept with methotrexate tapered and discontinued
Number of subjects: 59
Study 18779890 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept with continuous methotrexate
Number of subjects: 59
Study 16179044 — intervention group
Group type: EXPERIMENTAL
Intervention: Music
Number of subjects: 110
Study 16179044 — intervention group
Group type: COMPARATOR
Intervention: No music (Control)
Number of subjects: 110
Study 11836309 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg triptorelin
Number of subjects: 47
Study 11836309 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg leuprorelin
Number of subjects: 47
Study 11836309 — intervention group
Group type: COMPARATOR
Intervention: 10,000 IU hCG
Number of subjects: 47
Study 10744133 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Frequency Questionnaire (FFQ)
Number of subjects: 10913
Study 10744133 — intervention group
Group type: EXPERIMENTAL
Intervention: 13‐item dietary screener
Number of subjects: 10913
Study 10744133 — intervention group
Group type: COMPARATOR
Intervention: Comparison of FFQ and screener
Number of subjects: 10913
Study 7577200 — intervention group
Group type: EXPERIMENTAL
Intervention: Short, pulse-intensive (single-dose) treatment regimens
Number of subjects: 0
Study 7577200 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment regimens (implied control)
Number of subjects: 0
Study 1958002 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA 165 micrograms/day
Number of subjects: 210
Study 1958002 — intervention group
Group type: EXPERIMENTAL
Intervention: TAA 82.5 micrograms/day
Number of subjects: 210
Study 1958002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 7151268 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01 mg LT
Number of subjects: 12
Study 7151268 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg LT
Number of subjects: 12
Study 7151268 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31400644 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin alpha biosimilar (150 IU/day for 5 days, n=55)
Number of subjects: 110
Study 31400644 — intervention group
Group type: COMPARATOR
Intervention: Original follitropin alpha (150 IU/day for 5 days, n=55)
Number of subjects: 110
Study 31400644 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin alpha biosimilar
Number of subjects: 110
Study 31400644 — intervention group
Group type: COMPARATOR
Intervention: Original follitropin alpha
Number of subjects: 110
Study 29196298 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention (TRS 2°P)
Number of subjects: 16488
Study 26921245 — intervention group
Group type: EXPERIMENTAL
Intervention: APF530 250 mg
Number of subjects: 608
Study 26921245 — intervention group
Group type: EXPERIMENTAL
Intervention: APF530 500 mg
Number of subjects: 608
Study 26921245 — intervention group
Group type: COMPARATOR
Intervention: Palonosetron 0.25 mg
Number of subjects: 608
Study 25070172 — intervention group
Group type: EXPERIMENTAL
Intervention: GCDFP-15 positive tumors
Number of subjects: 602
Study 25070172 — intervention group
Group type: EXPERIMENTAL
Intervention: GCDFP-15 expression
Number of subjects: 602
Study 25070172 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological apocrine differentiation
Number of subjects: 602
Study 22190533 — intervention group
Group type: EXPERIMENTAL
Intervention: AAT (alpha‐1 antitrypsin)
Number of subjects: 13
Study 22190533 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 19436223 — intervention group
Group type: EXPERIMENTAL
Intervention: CE cream 0.3 mg daily for 12 weeks
Number of subjects: 423
Study 19436223 — intervention group
Group type: EXPERIMENTAL
Intervention: CE cream 0.3 mg twice weekly for 12 weeks
Number of subjects: 423
Study 19436223 — intervention group
Group type: EXPERIMENTAL
Intervention: CE cream 0.3 mg daily and twice weekly
Number of subjects: 423
Study 19436223 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 17154783 — intervention group
Group type: EXPERIMENTAL
Intervention: Change‐detection task with colored squares and pattern masks
Number of subjects: 0
Study 12846752 — intervention group
Group type: EXPERIMENTAL
Intervention: rhEPO in combination with intravenous iron
Number of subjects: 28
Study 12846752 — intervention group
Group type: COMPARATOR
Intervention: rhEPO alone
Number of subjects: 28
Study 10714731 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d of alendronate sodium
Number of subjects: 6588
Study 10714731 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 or 120 mg/d of raloxifene hydrochloride
Number of subjects: 6588
Study 9678115 — intervention group
Group type: EXPERIMENTAL
Intervention: Monophasic oral contraceptive containing 75 micrograms gestodene and 20 micrograms ethinylestradiol
Number of subjects: 25
Study 1626497 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill exercise testing
Number of subjects: 52
Study 1626497 — intervention group
Group type: COMPARATOR
Intervention: Cycle exercise testing
Number of subjects: 52
Study 6388452 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceforanide
Number of subjects: 220
Study 6388452 — intervention group
Group type: COMPARATOR
Intervention: Cephalothin
Number of subjects: 220
Study 30823818 — intervention group
Group type: EXPERIMENTAL
Intervention: MLS/I‐RSA approaches at rates from 100 to 1250 Hz
Number of subjects: 6
Study 30823818 — intervention group
Group type: COMPARATOR
Intervention: CONV averaging at rates of 25 and 100 Hz
Number of subjects: 6
Study 29266689 — intervention group
Group type: EXPERIMENTAL
Intervention: Social support from mothers
Number of subjects: 1519